We investigated the difference in survivin expression between a multidrug-resistant lung cancer cell line (H460/cDDP) and its parental counterpart (H460) and the influence of siRNA targeting survivin on the chemosensitivity of H460/cDDP. SiRNA targeting survivin was transfected into H460/cDDP cells using a liposome approach. Survivin mRNA and protein expression were significantly higher in H460/cDDP than H460 cells. The median inhibitory concentrations (IC 50 s) for cisplatin and paclitaxol in vitro against H460/cDDP cells were significantly lower in cells treated with survivin-specific siRNA than in control cells. Apoptosis and cleaved caspase-3 expression were analysed using annexin V and Western blotting, respectively, and showed a significant increase in apoptosis after treatment with the chemotherapeutic agents plus specific siRNA. Specific siRNA sensitized H460/cDDP cells to both cisplatin and paclitaxol. Thus, survivin appears to participate in the multidrug resistance mechanism of H460/cDDP cells and siRNA targeting survivin has the potential to increase the sensitivity of drug-resistant cancer cells to anticancer drugs.
Introduction
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide, with an increasing incidence and mortality rate. 1, 2 Surgical resection alone has been the standard of care for about 10% of NSCLC patients (stage I). 1, 2 Most NSCLC patients receive chemotherapy alone (stage IV) or in combination with other local treatment modalities (stage II, III). The success of chemotherapy depends upon the sensitivity of the tumour to these agents, however NSCLC often acquires resistance to drugs and even develops multiple drug resistance, which causes treatment failure. Chemotherapy kills cancer cells mainly by triggering apoptosis or programmed cell death, and evasion of apoptosis is one of the main reasons for chemoresistance. 3, 4 Survivin is a unique bifunctional inhibitor of apoptosis protein, which can suppress programmed cell death (apoptosis) 5, 6 and H Yang, J-H Fu, Y Hu et al. Survivin effect on H460/cDDP chemosensitivity regulate cell division. It is selectively upregulated in various cancers but downregulated or undetectable in normal adult tissues. 5 Survivin is maximally expressed during the G 2 -M phase in a cell cycledependent manner and is markedly depressed in the G 1 phase. 7 Survivin counteracts apoptotic stimuli of various kinds and thereby regulates G 2 -M phase progression. 8 Increasing expression of survivin may cause tumourigenesis by suppressing apoptosis and enhancing cell proliferation through mitosis. Overexpression of survivin in malignancies is considered an indicator of poor prognosis, associated with high tumour grade, rapid tumour progression, short patient survival, frequent recurrence and chemoresistance. 9 In NSCLC, survivin transcript detection by reverse transcriptase polymerase chain reaction (RT-PCR) 10 -12 or in situ hybridization 13 and protein expression 14 have been reported to be indicators of poor prognosis, associated with worse patient survival, low apoptotic index, high proliferation index and neoplastic vessel invasion. Reports have suggested that suppressing survivin expression by antisense oligonucleotide 12 and siRNA 15 sensitizes lung cancer cells to chemotherapy. Few studies, however, have examined chemoresistant lung cancer cell lines. 16, 17 Moreover, there are no reports that we are aware of relating survivin expression with NSCLC resistance to paclitaxol and very few that relate it to cisplatin, 16, 17 these being the two main agents in NSCLC chemotherapy. We were, therefore, interested in the role that survivin plays in the mechanism of NSCLC chemoresistance.
Materials and methods

CELL LINES AND CULTURE
The H460 and H460/cDDP cell lines were kindly provided by Dr J Xu (Guangzhou Medical College, Guangzhou, China). The human lung cancer cell line H460/cDDP was established by intermittent high-dose cisplatin selection (100 µmol/l) from the parental cell line H460. H460/cDDP cells were larger than H460 cells and possessed the typical multidrug resistant phenotype. With drug sensitivity detected by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, the resistance index to cisplatin and paclitaxol was 10.21 and 2193 (detected in a preliminary study), respectively. The H460/cDDP cells exhibited cross-resistance to 5-fluorouracil, adriamycin, etoposide and methotrexate. 18 Both cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 units/ml streptomycin in a humidified incubator containing 5% CO 2 at 37°C.
SEMI-QUANTITATIVE RT-PCR
Total RNA was isolated from H460 and H460/cDDP cells using TRIzol ® reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. RNA was quantified spectrophotometrically and its quality was checked by electrophoresis through denaturing agarose gels. Only samples that were not degraded, i.e. ones that showed clear 18S and 28S bands under ultraviolet light, were used for semiquantitative RT-PCR. Total RNA (0.5 µl) was reverse-transcribed using a First Strand cDNA Synthesis Kit (Toyobo, Osaka, Japan) in a total volume of 20 µl, containing 1 µl of Moloney murine leukaemia virus reverse transcriptase, 4 µl of 5× reverse transcriptase buffer (containing 25 mmol/l magnesium), 1 µl of deoxyribonucleotide triphosphate (dNTP) mixture (each 10 mmol/l), 1 µl of ribonuclease inhibitor (10 U/µl) and 1 µl of random primer (25 pmol/µl). Samples were incubated at 25°C for 10 min, 37°C H Yang, J-H Fu, Y Hu et al. Survivin effect on H460/cDDP chemosensitivity overnight, 75°C for 15 min and 4°C for 5 min. cDNA (0.5 µl) was then amplified by PCR using 0.25 µl of recombinant Taq DNA polymerase (Toyobo, Tokyo, Japan), 2 µl of 10× PCR buffer (20 mmol/l Tris-HCl, pH 8.0) and 4 µl of dNTP mixture (each 1 mmol/l), in a total volume of 20 µl. On the basis of the nucleotide sequence of survivin, 5′-CAGA TTTGAATCGCGGGACCC-3′ was used as the sense primer and 5′-CCAAGTCTGGCTCGT TCTCAG-3′ was used as the antisense primer. The amplification product was 206 base pairs (bp). β-Actin cDNA was amplified as an internal control; the sense primer for β-actin was 5′-CGGGACCTGACTGACTACCTCA-3′ and the antisense primer was 5′-TCAAGAAA GGGTGTAACGCAACTA-3′. The amplification product was 619 bp. The cycling conditions for both products were as follows: initial denaturation at 94°C for 5 min, followed by 30 cycles at 94°C for 45 s, 54°C for 30 s, 72°C for 45 s and, finally, 72°C for 5 min. The PCR products were separated on 2% agarose gels and visualized by staining with ethidium bromide. Semi-quantitative analysis was performed with Glyko ® Bandscan version 5.0 (Glyko Inc., Novato, CA, USA). The ratio of the photodensity of the RT-PCR products of survivin and β-actin was used as the measure of survivin mRNA expression.
WESTERN BLOTTING
Cells were washed with 10 mM phosphatebuffered saline (PBS), pH 7.4, and lysed on plates in ice-cold cell extract buffer containing Tris-HCl (pH 6.8), 2% sodium dodecyl sulphate (SDS), 10% glycerol, 50 mM dithiothreitol and 0.1% bromophenol blue. The protein concentrations were determined using a DU ® 800 spectrophotometer (Beckman Coulter, Fullerton, CA, USA). Equal amounts of proteins (8 µg/well) were subjected to electrophoresis using 15% SDS-polyacrylamide gels followed by electrophoretic transfer of proteins onto polyvinylidene difluoride membranes (Amersham Biosciences, Piscataway, NJ, USA). Membranes were incubated in Trisbuffered saline (2 mM Tris, 15 mM NaCl, pH 7.6) containing 5% (w/v) non-fat dry milk and 0.2% (v/v) Tween 20 for 1 h at room temperature and then probed with the following primary antibodies (all from Cell Signaling Technology, Beverly, MA, USA): mouse monoclonal anti-survivin antibody, mouse monoclonal anti-caspase-3 antibody and rabbit monoclonal anti-glyceraldehyde-3phosphate dehydrogenase (GAPDH) antibody overnight at 4°C, followed by incubation with horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences) for 1 h at room temperature. Finally, the protein bands were visualized on X-ray sensitive film using an enhanced chemiluminescence detection system (Amersham Biosciences). Glyko ® Bandscan version 5.0 (Glyko Inc.), gel digitizing software was used to quantify the intensity of each band on the X-ray film. The ratio of the intensity of the survivin and GAPDH bands was used as the measure of survivin protein expression.
MTT ASSAY
The cytotoxicities of cisplatin and paclitaxol were determined using the MTT assay. Cells were plated in 200 µl of medium per well in 96-well plates. Following overnight incubation, the medium was removed and replaced by seven 50% serial dilutions of 50 mg/l cisplatin and seven 50% serial dilutions of 40 mg/l paclitaxol. After incubation for 48 h, MTT was added (100 µl/well of a 1 mg/ml MTT solution in culture medium), followed by 4 h of incubation at 37°C. The MTT solution was then removed and the insoluble formazan crystals were dissolved in 100 µl of dimethyl sulphoxide. The plates were agitated and the absorbance was measured H Yang, J-H Fu, Y Hu et al. Survivin effect on H460/cDDP chemosensitivity at 540 nm using a microtitre plate spectrophotometer (Multiskan MCC/340P, version 2.20, Titertek MK II; Labsystems, Brussels, Belgium).
SIRNA
SiRNAs against survivin were synthesized by Dharmacon Inc. (Lafayette, CO, USA). All siRNAs were duplexed, desalted, 2′ deprotected and purified (> 80%) by Dharmacon Inc. The survivin siRNA sequence was: 5′-AAGGCUGGGAGCCAGAUGACGdTdT-3′. 19 The scramble (control) siRNA sequence was: 5′-AAGGCUAAGGGGCCGAUGACGdTdT-3′.
TRANSFECTION OF SIRNA
H460/cDDP cells (3 × 10 5 cells/p35 dish) were transfected using lipofectamine (Lipofectamine™ 2000; Invitrogen) according to the manufacturer's instructions, as follows: lipofectamine plus scramble (control) siRNA; lipofectamine plus survivin siRNA; lipofectamine alone; or distilled water (blank control). The ratio of siRNAs: lipofectamine was 1:3. The common complete medium was replaced by antibiotic-free medium containing serum 24 h before the transfection. At the start, the medium was replaced by 250 µl of antibiotic-free Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Then 0.39 µl lipofectamine (diluted in 125 µl of Opti-MEM medium [Invitrogen] and incubated for < 15 min at room temperature) was mixed with siRNAs (0.5 µl of 20 µmol/l siRNA duplex diluted in 125 µl of Opti-MEM [which gives 20 nM siRNA] for < 5 min at room temperature). The mixture was then incubated for 20 min at room temperature and added to the cells. The cells were incubated at 37°C in a humidified CO 2 incubator for 6 h and then re-cultured in 2 ml of complete medium and analysed using the MTT and Western blot assays as described above.
ANNEXIN V APOPTOSIS ASSAY
To evaluate apoptosis the annexin V-fluorescein isothiocyanate (FITC) method was performed on H460/cDDP cells exposed to 12 mg/l cisplatin or 15 mg/l paclitaxol for 48 h, after lipofectamine transfection of 20 nM survivin siRNA, 20 nM scramble (control) siRNA or distilled water for 24 h. An annexin V-FITC detection kit incorporating propidium iodide (PI) was used as described by the manufacturer's protocol (Invitrogen). Cells were harvested with 0.1% trypsin and 0.01% ethylenediamine tetraacetic acid in PBS, washed with normal medium and cold PBS, and resuspended in 500 µl binding buffer. Annexin (5 µl) and 5 µl PI were added to the cells, which were then vortexed and incubated for 15 min in the dark. Samples were analysed by flow cytometry using the FITC and PI labels, and 10 000 events were counted for each sample.
STATISTICAL ANALYSIS
Data are expressed as mean ± SD. Statistical significance was determined by the Student t-test. A P-value < 0.05 was considered to be statistically significant.
Results
SURVIVIN EXPRESSION IN H460 VERSUS H460/CDDP
Survivin expression of H460/cDDP cells was up-regulated compared with H460 cells. The levels of survivin mRNA (semi-quantitative RT-PCR, 1.10 ± 0.20 versus 0.13 ± 0.03, P < 0.01; Fig. 1 ) and survivin protein (by Western blot analysis; 0.30 ± 0.06 versus 0.11 ± 0.02, P < 0.01; Fig. 2 ) were significantly higher in H460/ cDDP cells than in H460 cells, respectively. To minimize the potential toxicity from duplex siRNA, we used 20 nM in our experiment. The relative survivin protein levels 48 h after transfection, in the blank control, survivin siRNA, scramble (control) siRNA and lipofectamine alone groups were 0.35 ± 0.10, 0.10 ± 0.01, 0.36 ± 0.08 and 0.37 ± 0.13, respectively (F = 6.19, P = 0.018; Figs  3A and 3B ). The expression of survivin protein in H460/cDDP cells transfected with survivin siRNA was significantly down-regulated compared with the blank control group (P = 0.024). Survivin siRNA (20 nM) reduced the survivin protein level by 67.0%, 76.2% and 92.3% after 24, 48 and 72 h, respectively (Fig. 3C ). The effects of scramble (control) siRNA and lipofectamine alone on the level of survivin protein expression were minimal compared with the blank control.
DOWN-REGULATING EFFECTS OF SIRNA ON SURVIVIN PROTEIN EXPRESSION
INHIBITION OF SURVIVIN EXPRESSION SENSITIZES H460/CDDP TO CHEMOTHERAPY
Cisplatin and paclitaxol were both cytotoxic to H460/cDDP cells (MTT assay). To expression could sensitize H460/cDDP cells to chemotherapy, cells were treated with both siRNA targeting survivin and chemotherapy agents. In the blank control, survivin-specific siRNA, scramble siRNA and lipofectamine alone groups, the median inhibitory concentrations (IC 50 s) for cisplatin were 6.34 ± 0.60 mg/l, 4.01 ± 0.88 mg/l, 6.27 ± 0.27 mg/l and 6.83 ± 0.66 mg/l, respectively (F = 13.53, P = 0.001) and the IC 50 s for paclitaxol were 12.70 ± 1.21 mg/l, 8.11 ± 1.70 mg/l, 12.74 ± 1.75 mg/l and 11.43 ± 0.83 mg/l, respectively (F = 8.81, P = 0.004). The inhibition of survivin expression by siRNA significantly reduced the cisplatin IC 50 by 36.75% (P = 0.002) and decreased the paclitaxol IC 50 by 36.14% (P = 0.003) compared with the blank controls. Scramble (control) siRNA and lipofectamine alone had little effect on the chemosensitivity of H460/cDDP cells compared with the blank control.
The results of the annexin V assay to evaluate apoptosis in H460/cDDP cells exposed to 12 mg/l cisplatin or 15 mg/l paclitaxol for 48 h after lipofectamine transfection of 20 nM survivin siRNA, 20 nM scramble (control) siRNA or distilled water for 24 h are given in Fig. 4 and Table 1 (cisplatin) and Fig. 5 and Table 2 (paclitaxol). The percentages of total apoptosis after treatment with cisplatin alone, or in combination with scramble To give additional confirmation of these observations, levels of cleaved caspase-3 were measured using Western blot analysis.
Cleaved caspase-3 levels in the blank control, survivin siRNA and scramble siRNA groups that were treated with cisplatin were 0.45 ± 0.03, 0.78 ± 0.07 and 0.46 ± 0.05, respectively (F = 48.70, P < 0.05; Fig. 6 ). The level was significantly higher in the survivin siRNA group compared with the blank control group (P < 0.05), but not significantly different in the blank control compared with the scramble (control) siRNA group. Cleaved H Yang, J-H Fu, Y Hu et al. Survivin effect on H460/cDDP chemosensitivity caspase-3 levels in the blank control, survivin siRNA and scramble siRNA groups that were treated with paclitaxol were 0.39 ± 0.03, 1.01 ± 0.12 and 0.40 ± 0.04, respectively (F = 78.92, P < 0.05; Fig. 7) . The level was also significantly higher in the survivin siRNA group compared with the blank control group (P < 0.05), but not significantly different in the blank control compared with the scramble (control) siRNA group.
Discussion
It has been reported that survivin is overexpressed in NSCLC. 10 -14 Nakano et al. 11 detected survivin mRNA in squamous cell carcinoma, adenocarcinoma and large cell carcinoma of the lung using RT-PCR. Tamm et al. 6 used RT-PCR to demonstrate survivin expression in 60 human cancer cell lines and found that the level in lung cancer cell lines was the highest. The over-expression of survivin in tumours has been linked to poor 12 -14 The present study looked at the expression of survivin in the large cell lung cancer cell lines, H460 and H460/cDDP and, using RT-PCR and Western blot analysis, demonstrated that survivin expression was significantly greater in the multidrug resistant cell line H460/cDDP than in the sensitive cell line H460.
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was established by intermittently treating the parental cell line H460 with high-dose cisplatin. Cisplatin caused the H460 cell line to mutate into resistant cells and, thereby, perpetuate the resistance character. Survivin expression can be related to the multidrug resistance of H460/cDDP cells, since cisplatin has been shown to induce increased survivin 25 -27 and DNA damage repair. 28, 29 To determine the importance of survivin in the chemoresistance of H460/cDDP cells, we tested the effect of survivin expression inhibition by siRNA on chemoresistance.
Our study suggests that survivin-specific siRNA blocks expression at the mRNA and protein levels. MTT analysis revealed that silencing survivin at these levels sensitized H460/cDDP cells to cisplatin and paclitaxol. Annexin V assay confirmed that the increase Survivin effect on H460/cDDP chemosensitivity in chemosensitivity was associated with an increase in apoptosis. It has been reported that survivin may block apoptosis by inhibiting caspase-3 and caspase-7 activities directly. 5, 6 We also identified an increased cleaved caspase-3 level (which indicates activation of caspase-3) in cells exposed to chemotherapy after treatment with survivin siRNA. Activation of caspase-3 by inhibiting survivin expression may, thus, increase sensitivity to chemotherapy.
H460/cDDP cells have other mechanisms of chemoresistance. Wang et al. 30 demonstrated that H460/cDDP cells (unlike H460 cells) cannot phosphorylate p53 protein, and that transfection with plasmid pShuttle-CMV-wtp53 cDNA partially reversed (53.2%) resistance to cisplatin in H460/cDDP cells. Previous reports had suggested that p53 down-regulates the expression of survivin in some cell models and cancer cell lines. 31, 32 There is a possibility that survivin in GAPDH H460/cDDP cells might be up-regulated as a result of p53 mutations. 33, 34 We found that suppression of survivin reduced the cisplatin IC 50 of H460/cDDP cells by 36.75% and decreased the paclitaxol IC 50 by 36.14%, indicating that survivin is a factor involved in the multidrug resistance of H460/cDDP. Clinical studies are required to determine whether the survivin status of NSCLC patients can predict poor response to cisplatin or paclitaxol.
In conclusion, siRNA targeting survivin has the potential to increase the sensitivity of drug-resistant cancer cells to anticancer drugs.
